Alkermes (ALKS) Downgraded to Underperform
July 07, 2010 at 05:38 AM EDT
Alkermes, Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of $0.12 per share compared with a loss of $0.13 in the year-ago period. Revenues in the quarter slipped 12.3% due to lower manufacturing revenues for Risperdal Consta. We believe that even if Alkermes diabetes candidate Bydureon is approved by the US FDA later in [...]
